DOCSLIB.ORG

Keratinocyte-Specific Mesotrypsin Contributes to the Desquamation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Keratinocyte-Specific Mesotrypsin Contributes to the Desquamation View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE Keratinocyte-Specific Mesotrypsin Contributes to the Desquamation Process via Kallikrein Activation and LEKTI Degradation Masashi Miyai1,3, Yuuko Matsumoto1,3, Haruyo Yamanishi1, Mami Yamamoto-Tanaka1,2, Ryoji Tsuboi2 and Toshihiko Hibino1 Kallikrein-related peptidases (KLKs) have critical roles in corneocyte desquamation and are regulated by lymphoepithelial Kazal-type inhibitor (LEKTI). However, it is unclear how these proteases are activated and how activated KLKs are released from LEKTI in the upper cornified layer. Recently, we reported cloning of a PRSS3 gene product, keratinocyte-specific mesotrypsin, from a cDNA library. We hypothesized that mesotrypsin is involved in the desquamation process, and the aim of the present study was to test this idea by examining the effects of mesotrypsin on representative desquamation-related enzymes pro-KLK5 and pro-KLK7. Incubation of mesotrypsin and these zymogens resulted in generation of the active forms. KLK activities were effectively inhibited by recombinant LEKTI domains D2, D2–5, D2–6, D2–7, D5, D6, D6–9, D7, D7–9, and D10–15, whereas mesotrypsin activity was not susceptible to these domains, and in fact degraded them. Immunoelectron microscopy demonstrated that mesotrypsin was localized in the cytoplasm of granular cells and intercellular spaces of the cornified layer. Proximity ligation assay showed close association between mesotrypsin and KLKs in the granular to cornified layers. Age-dependency analysis revealed that mesotrypsin was markedly down- regulated in corneocyte extract from donors in their sixties, compared with younger donors. Collectively, our findings suggest that mesotrypsin contributes to the desquamation process by activating KLKs and degrading the intrinsic KLKs’ inhibitor LEKTI. Journal of Investigative Dermatology (2014) 134, 1665–1674; doi:10.1038/jid.2014.3; published online 30 January 2014 INTRODUCTION chymotrypsin-like enzyme (stratum corneum chymotryptic Epidermal differentiation is precisely controlled, and the thick- enzyme) (Lundstrom and Egelrud, 1991) have roles in the ness of the epidermis is maintained through constant shedding detachment of superficial corneocytes. Later, these proteases of the outermost layers of corneocytes, a process known as were identified as KLK5 and KLK7, respectively (Caubet et al., desquamation (Watt, 1989). Desquamation is accomplished by 2004). Recent investigations have suggested that other KLK– the degradation of corneodesmosomes, which are involved in related enzymes, including KLKs 6, 8, 10, 11, 13, and 14, are corneocyte–corneocyte adherence (Caubet et al., 2004; Ishida- also expressed in human epidermis, and it was suggested that Yamamoto and Kishibe, 2011). Corneodesmosomes are com- they may form a proteolytic cascade that results in desquama- posed of three major proteins: desmoglein 1, desmocollin, and tion (Komatsu et al., 2007). All KLKs are synthesized as corneodesmosin. These proteins are proteolytically hydrolyzed proenzymes, and subsequently activated through mechanisms by a family of kallikrein-related peptidases (KLKs). Earlier that have not yet been established. KLK5 is thought to be the studies demonstrated that a trypsin-like enzyme (stratum initiator of this cascade, as it is capable of activating most of the corneum tryptic enzyme) (Suzuki et al., 1993) and a family members (Ishida-Yamamoto et al., 2011). Desquamation is regulated not only by proteases involved 1Shiseido Research Center, Kanazawa-ku, Yokohama, Japan and 2Department in the activation cascade but also by inhibitors such as of Dermatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan lymphoepithelial Kazal-type related inhibitor (LEKTI), a pro- 3These authors contributed equally to this work. duct of the serine protease inhibitor Kazal-type 5 gene SPINK5 Correspondence: Toshihiko Hibino, Shiseido Research Center, 2-12-1 Fukuura, (Borgono et al., 2007; Roelandt et al., 2009). LEKTI consists of Kanazawa-ku 236-8643, Yokohama, Japan. 15 serine protease-inhibitory domains and is believed to be E-mail: [email protected] processed to single or multiple domains to facilitate specific Abbreviations: KLK, kallikrein-related peptidase; LEKTI, lymphoepithelial inhibition of particular proteases. Recently, LEKTI2 encoded Kazal-type inhibitor; PBS, phosphate-buffered saline; PLA, proximity ligation by SPINK9 was identified in the palmoplantar epidermis and assay was found to show KLK5–specific inhibition (Brannstrom Received 12 June 2013; revised 15 October 2013; accepted 15 October 2013; accepted article preview online 3 January 2014; published online et al., 2012). SPINK6 was isolated from human plantar 30 January 2014 stratum corneum extracts as a selective inhibitor of KLK5, 7, & 2014 The Society for Investigative Dermatology www.jidonline.org 1665 MMiyaiet al. Involvement of Mesotrypsin in Desquamation and 14 (Meyer-Hoffert et al., 2010). Thus, KLK activities seem mesotrypsin (Figure 1b). In addition, incubation of pro-KLK5 to be strongly suppressed under physiological conditions. with mesotrypsin resulted in a time-dependent linear increase It is suggested that active KLKs are dissociated from various of KLK5 activity (Figure 1c). Similar results were obtained for SPINK gene products under acidic conditions at the skin pro-KLK7 (Figure 1d–f). These results clearly indicate that surface (Pampalakis and Sotiropoulou, 2007). However, mesotrypsin generates active KLKs through limited proteolysis Ishida-Yamamoto et al. (2012) clearly demonstrated that of pro-KLKs. degradation of corneodesmosomes starts deeper in the corni- fied layers. Thus, it is plausible that dissociation of active KLKs Inhibition of KLK5 by LEKTI domains and the effect of pH on the from their inhibitors is not a cell-surface event, but is interaction controlled at least in part by mechanisms other than pH. Next, we generated various fragments of LEKTI (D2, D2–5, On the other hand, we have cloned an epidermis-specific D2–6, D2–7, D5, D6, D7, D7–9, D8–9, and D10–15), splicing variant of PRSS3 gene, trypsinogen 5, from a kerati- covering the whole length of the LEKTI protein (Figure 2a). nocyte cDNA library (Nakanishi et al., 2010). Trypsinogen 5 All of these LEKTI fragments were able to inhibit KLK5 activity possesses a very short N-terminal propeptide followed by the (Figure 2b). The inhibitory concentration 50 (IC50) values are enterokinase recognition sequence DDDDK-I. After cleavage shown in Figure 2c. D2 showed a high IC50 value for KLK5 by enterokinase, the same mesotrypsin would be produced as compared with other domains, indicating that D2 may not be from pancreatic trypsinogen 3 and brain-type trypsinogen 4. an effective inhibitor of KLK5. Similarly, all LEKTI fragments We confirmed that epidermal mesotrypsin is expressed in the were able to inhibit KLK7 activity (Supplementary Figure S1 upper epidermis, whereas its activating enzyme, enterokinase, online). Each domain construct showed somewhat weaker shows a more confined localization in the boundary area inhibition of KLK7, compared with KLK5, and none of these between the granular layer and cornified layer. Characteristic LEKTI domains showed a clear preference for KLK7 inhibition. features of mesotrypsin are as follows: (1) it cannot digest high- Next, we tested whether inhibition of KLK5 by LEKTI domains molecular-weight proteins, in contrast to anionic trypsin and was abrogated under acidic conditions (Figure 2d). KLK5 was cationic trypsin, the PRSS1 and PRSS2 gene products, incubated with D5 or D6 in buffers of different pH values. respectively, and (2) it is not susceptible to naturally KLK5 was active between pH 5.5 and pH 9, and D5 and D6 occurring trypsin inhibitors (Nyaruhucha et al., 1997). Thus, completely suppressed KLK5 activity in this pH range. These the physiological role of mesotrypsin is likely to be completely results indicate that loss of LEKTI inhibition of KLKs may not different from those of trypsins. Instead, it seems likely to be occur simply as a result of the acidic pH typically observed at involved in limited proteolysis, such as zymogen activation. the skin surface. Furthermore, it is capable of inactivating naturally occurring trypsin inhibitors by proteolytic cleavage. These unique pro- Mesotrypsin degrades various LEKTI domains perties of mesotrypsin led us to hypothesize that epidermal Next, we tested the effect of these LEKTI constructs on the mesotrypsin is involved in the desquamation process. To test activity of mesotrypsin (Figure 3a). None of these LEKTI this idea, we focused on two critical processes. One is the constructs inhibited mesotrypsin activity even in the presence activation of pro-KLK5 and the other is dissociation of active of 1,000-fold excess of recombinant LEKTIs. These results KLKs from LEKTI proteins. Furthermore, we examined the indicate that mesotrypsin is resistant to intrinsic serine pro- localization of mesotrypsin in human epidermis using tease inhibitors, including LEKTI. We then examined whether immunoelectronmicroscopy. Further, in situ proximity ligation the LEKTI constructs were degraded by mesotrypsin, using assay (PLA) was used to assess the interaction of mesotrypsin newly prepared antibodies against D2 and D12, and commer- with KLKs or LEKTI proteins in human epidermis. cially available anti-D4–8 antibody (F2). The N-terminal domains of LEKTI (D2 and D2–7), the inner domains (D5, RESULTS
Load more

Recommended publications
  • Newly Developed Serine Protease Inhibitors Decrease Visceral Hypersensitivity in a Post-Inflammatory Rat Model for Irritable Bowel Syndrome
    This item is the archived peer-reviewed author-version of: Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome Reference: Ceuleers Hannah, Hanning Nikita, Heirbaut Leen, Van Remoortel Samuel, Joossens Jurgen, van der Veken Pieter, Francque Sven, De Bruyn Michelle, Lambeir Anne-Marie, de Man Joris, ....- New ly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bow el syndrome British journal of pharmacology - ISSN 0007-1188 - 175:17(2018), p. 3516-3533 Full text (Publisher's DOI): https://doi.org/10.1111/BPH.14396 To cite this reference: https://hdl.handle.net/10067/1530780151162165141 Institutional repository IRUA NEWLY DEVELOPED SERINE PROTEASE INHIBITORS DECREASE VISCERAL HYPERSENSITIVITY IN A POST-INFLAMMATORY RAT MODEL FOR IRRITABLE BOWEL SYNDROME. Running title: Serine proteases in visceral hypersensitivity Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Samuel Van Remoortel, Michelle De bruyn, Jurgen Joossens, Pieter van der Veken, Anne-Marie Lambeir, Sven M Francque, Joris G De Man, Jean-Pierre Timmermans, Koen Augustyns, Ingrid De Meester, Benedicte Y De Winter Hannah Ceuleers, Nikita Hanning, Jelena Heirbaut, Sven Francque, Joris G De Man, Benedicte Y De Winter, Laboratory of Experimental Medicine and Pediatrics, Division of Gastroenterology, University of Antwerp, Antwerp, Belgium. Samuel Van Remoortel, Jean-Pierre Timmermans, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium. Jurgen Joossens, Pieter van der Veken, Koen Augustyns, Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium. Sven Francque, Antwerp University Hospital, Antwerp, Belgium. Michelle De bruyn, Anne-Marie Lambeir, Ingrid De Meester, Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
    [Show full text]
  • PRSS3 Monoclonal Antibody (419911) Catalog Number MA5-24156 Product Data Sheet
    Lot Number: TC2545731D Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 thermofisher.com/contactus PRSS3 Monoclonal Antibody (419911) Catalog Number MA5-24156 Product Data Sheet Details Species Reactivity Size 100 µg Tested species reactivity Mouse Host / Isotype Rat IgG1 Tested Applications Dilution * Class Monoclonal Immunohistochemistry (Frozen) 8-25 µg/ml Type Antibody (IHC (F)) Clone 419911 * Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls. Mouse myeloma cell line Immunogen NS0-derived recombinant mouse Trypsin 3/PRSS3 Phe16-Asn246 Conjugate Unconjugated Form Lyophilized Concentration 0.5mg/ml Purification Protein A/G Storage Buffer PBS with 5% trehalose Contains No Preservative Storage Conditions -20° C, Avoid Freeze/Thaw Cycles Product Specific Information Reconstitute at 0.5 mg/mL in sterile PBS. Background/Target Information PRSS3 encodes a trypsinogen, which is a member of the trypsin family of serine proteases. This enzyme is expressed in the brain and pancreas and is resistant to common trypsin inhibitors. It is active on peptide linkages involving the carboxyl group of lysine or arginine. PRSS3 is localized to the locus of T cell receptor beta variable orphans on chromosome 9. Four transcript variants encoding different isoforms have been described for this gene. For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
    [Show full text]
  • Irf2)Intrypsinogen5 Gene Transcription
    Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2)intrypsinogen5 gene transcription Hideki Hayashia, Tomoko Kohnoa, Kiyoshi Yasuia, Hiroyuki Murotab, Tohru Kimurac, Gordon S. Duncand, Tomoki Nakashimae, Kazuo Yamamotod, Ichiro Katayamab, Yuhua Maa, Koon Jiew Chuaa, Takashi Suematsua, Isao Shimokawaf, Shizuo Akirag, Yoshinao Kuboa, Tak Wah Makd,1, and Toshifumi Matsuyamaa,h,1 aDivision of Cytokine Signaling, Department of Molecular Biology and Immunology and fDepartment of Investigative Pathology, Nagasaki University Graduate School of Biomedical Science, Nagasaki 852-8523, Japan; Departments of bDermatology and cPathology, Graduate School of Medicine and gDepartment of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; dCampbell Family Cancer Research Institute, Princess Margaret Hospital, Toronto, ON, Canada M5G 2M9; eDepartment of Cell Signaling, Tokyo Medical and Dental University, Tokyo 113-8549, Japan; and hGlobal Center of Excellence Program, Nagasaki University, Nagasaki 852-8523, Japan Contributed by Tak Wah Mak, October 5, 2011 (sent for review September 8, 2011) − − Mice deficient for interferon regulatory factor (Irf)2 (Irf2 / mice) transcriptional activation of dsRNA-sensing PRRs were critical for exhibit immunological abnormalities and cannot survive lympho- the pIC-induced death. cytic choriomeningitis virus infection. The pancreas of these ani- mals is highly inflamed, a phenotype replicated by treatment with Results and Discussion − − poly(I:C), a synthetic double-stranded RNA. Trypsinogen5 mRNA Irf2 / Mice Show IFN-Dependent Poly(I:C)-Induced Pancreatitis and −/− IFN-Independent Secretory Dysfunction in Pancreatic Acinar Cells. was constitutively up-regulated about 1,000-fold in Irf2 mice − − LCMV-infected Irf2 / mice die within 4 wk postinfection (3), compared with controls as assessed by quantitative RT-PCR.
    [Show full text]
  • PRSS3 Is a Prognostic Marker in Invasive Ductal Carcinoma of the Breast
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 13), pp: 21444-21453 Research Paper PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast Li Qian1,*, Xiangxiang Gao2,*, Hua Huang1, Shumin Lu3, Yin Cai3, Yu Hua3, Yifei Liu1, Jianguo Zhang1 1Department of Clinical Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China 2Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong, Jiangsu, China 3Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China *These authors contributed equally to this work Correspondence to: Jianguo Zhang, email: [email protected] Yifei Liu, email: [email protected] Keywords: invasive ductal carcinoma, immunohistochemistry, PRSS3, prognosis Received: November 08, 2016 Accepted: January 27, 2017 Published: February 21, 2017 ABSTRACT Objective: Serine protease 3 (PRSS3) is an isoform of trypsinogen, and plays an important role in the development of many malignancies. The objective of this study was to determine PRSS3 mRNA and protein expression levels in invasive ductal carcinoma of the breast and normal surrounding tissue samples. Results: Both PRSS3 mRNA and protein levels were significantly higher in invasive ductal carcinoma of the breast tissues than in normal or benign tissues (all P < 0.05). High PRSS3 protein levels were associated with patients’ age, histological grade, Her-2 expression level, ki-67 expression, and the 5.0-year survival rate. These high protein levels are independent prognostic markers in invasive ductal carcinoma of the breast. Materials and Methods: We used real-time quantitative polymerase chain reactions (N = 40) and tissue microarray immunohistochemistry analysis (N = 286) to determine PRSS3 mRNA and protein expression, respectively.
    [Show full text]
  • Human Trypsin-3 / PRSS3 Protein (His Tag)
    Human Trypsin-3 / PRSS3 Protein (His Tag) Catalog Number: 11866-H08H General Information SDS-PAGE: Gene Name Synonym: MTG; PRSS4; RP11-176F3.3; T9; TRY3; TRY4 Protein Construction: A DNA sequence encoding the human PRSS3 isoform c (P35030-3) (Met 1- Ser 247) was expressed, with a polyhistidine tag at the C-terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Bio Activity： Protein Description Measured by its ability to cleave the fluorogenic peptide substrate, Mca- RPKPVE-Nval-WRK(Dnp)-NH2 (AnaSpec, Catalog#27114) . The specific Trypsin-3, also known as Trypsin III, brain trypsinogen, Serine protease 3 activity is >4,000 pmoles/min/μg. (Activation description: The proenzyme and PRSS3, is a secreted protein which belongs to thepeptidase S1 family. needs to be activated by enteropeptidase for an activated form) Trypsin-3 / PRSS3 is expressed is in pancreas and brain. It contains onepeptidase S1 domain. Trypsin-3 / PRSS3 can degrade intrapancreatic Endotoxin: trypsin inhibitors that protect against CP. Genetic variants that cause higher mesotrypsin activity might increase the risk for chronic pancreatitis < 1.0 EU per μg of the protein as determined by the LAL method (CP). A sustained imbalance of pancreatic proteases and their inhibitors seems to be important for the development of CP. The trypsin inhibitor- Stability: degrading activity qualified PRSS3 as a candidate for a novel CP Samples are stable for up to twelve months from date of receipt at -70 ℃ susceptibility gene. Trypsin-3 / PRSS3 has been implicated as a putative tumor suppressor gene due to its loss of expression, which is correlated Predicted N terminal: Val 16 with promoter hypermethylation, in esophageal squamous cell carcinoma and gastric adenocarcinoma.
    [Show full text]
  • Supplementary Table 1: Gene List of 44 Upregulated Enzymes in Transformed Mesenchymal Stem Cell Cancer Model
    Supplementary Table 1: Gene list of 44 upregulated enzymes in transformed mesenchymal stem cell cancer model. Gene expression values for parental MSC (MSC 0) and transformed MSC (MSC5) are an average of three replicate log-2 transformed expression values from affymetrix U133 plus 2 genechip experiments with the log-fold change (LFC) indicating the difference (MSC5-MSC0). Supplementary Table 1 HGNC Symbol Alias Enzyme ID U133 plus2 probe set MSC0 MSC5 LFC Ttest pval # Gene rifs # Pubmed cites from Genecards (Sep 2007) Pathway / Function PharmGKB Drugs? Drug pathways? Therapeutic Target Database Thomson Pharma RNASEH2A AGS4; JUNB; RNHL; RNHIA; RNASEHI 3.1.26.- 203022_at 8.56 9.87 1.31 1.56E-05 0 11 RNA degradation none none none PPAP2C LPP2; PAP-2c; PAP2-g 3.1.3.4 209529_at 6.48 8.63 2.16 5.74E-03 2 13 Glycerolipid synthesis none none none ADARB1 ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c 3.5.-.- 234799_at 6.36 8.15 1.79 2.03E-04 10 58 RNA pre-mRNA editing none none none ADARB1 3.5.-.- 203865_s_at 6.99 8.42 1.43 6.94E-03 10 58 RNA pre-mRNA editing none none none UAP1 AgX; AGX1; SPAG2 2.7.7.23 209340_at 11.17 12.45 1.28 2.46E-07 0 37 polysaccharide synthesis none none RNMT MET; RG7MT1; hCMT1c; KIAA0398; DKFZp686H1252 2.1.1.56 202684_s_at 5.70 6.78 1.08 8.15E-03 1 24 RNA (mRNA) capping none none GPD2 GDH2, mGPDH 1.1.1.8 211613_s_at 5.71 6.73 1.02 7.02E-03 2 37 glycolysis none none GCDH ACAD5, GCD 1.3.99.7 237304_at 5.38 6.39 1.01 2.44E-02 4 63 lys, hydroxy-lys, and trp metabolism none none ESPL1 3.4.22.49 38158_at 8.03
    [Show full text]
  • Epithelial Expression and Function of Trypsin-3 in Irritable
    Neurogastroenterology ORIGINAL ARTICLE Epithelial expression and function of trypsin-3 in irritable bowel syndrome Claire Rolland-Fourcade,1 Alexandre Denadai-Souza,1 Carla Cirillo,2 Cintya Lopez,3 Josue Obed Jaramillo,3 Cleo Desormeaux,1 Nicolas Cenac,1 Jean-Paul Motta,1 Muriel Larauche,4 Yvette Taché,4 Pieter Vanden Berghe,2 Michel Neunlist,5,6,7 Emmanuel Coron,5,6,7 Sylvain Kirzin,8 Guillaume Portier,8 Delphine Bonnet,8 Laurent Alric,8 Stephen Vanner,3 Celine Deraison,1 Nathalie Vergnolle1,9 ► Additional material is ABSTRACT published online only. To view Objectives Proteases are key mediators of pain and Significance of this study please visit the journal online (http:// dx. doi. org/ 10. 1136/ altered enteric neuronal signalling, although the types gutjnl- 2016- 312094). and sources of these important intestinal mediators are unknown. We hypothesised that intestinal epithelium is What is already known on this subject? For numbered affiliations see ▸ end of article. a major source of trypsin-like activity in patients with IBS Colonic tissues from patient with IBS release and this activity signals to primary afferent and enteric ‘trypsin-like’ activity. Correspondence to nerves and induces visceral hypersensitivity. ▸ Proteases in general and trypsins specifically Dr Nathalie Vergnolle, Inserm Design Trypsin-like activity was determined in tissues can signal to enteric neurons. UMR-1220, Institut de from patients with IBS and in supernatants of Caco-2 ▸ Protease-activated receptor-2 activation can be Recherche en Santé Digestive, cells stimulated or not. These supernatants were also activated on mouse sensory neurons and CS60039 CHU Purpan, Toulouse, Cedex-3 31024, applied to cultures of primary afferents.
    [Show full text]
  • Trypsin (PRSS3) (Center) Rabbit Polyclonal Antibody Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AP53469PU-N Trypsin (PRSS3) (Center) Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: FC, IHC, WB Recommended Dilution: ELISA: 1/1000. Western Blot: 1/100-1/500. Flow Cytometry: 1/10-1/50. Immunohistochemistry on Paraffin Sections: 1/10-1/50. Reactivity: Human Host: Rabbit Isotype: Ig Clonality: Polyclonal Immunogen: KLH conjugated synthetic peptide between 143-171 amino acids from the Central region of Human Trypsin-3 / PRSS3 Specificity: This antibody recognizes Human Trypsin-3 / PRSS3 (Center). Formulation: PBS containing 0.09% (W/V) sodium azide as preservative State: Aff - Purified State: Liquid purified Ig fraction Concentration: lot specific Purification: Affinity Chromatography on Protein A Conjugation: Unconjugated Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. Gene Name: Homo sapiens T cell receptor beta variable orphans on chromosome 9 (TRBVOR9@) on chromosome 9 Database Link: Entrez Gene 5646 Human P35030 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 Trypsin (PRSS3) (Center) Rabbit Polyclonal Antibody – AP53469PU-N Background: This gene encodes a trypsinogen, which is a member of the trypsin family of serine proteases. This enzyme is expressed in the brain and pancreas and is resistant to common trypsin inhibitors.
    [Show full text]
  • PRSS3 Polyclonal Antibody Catalog Number PA5-48034 Product Data Sheet
    Lot Number: TA2504173B Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 thermofisher.com/contactus PRSS3 Polyclonal Antibody Catalog Number PA5-48034 Product Data Sheet Details Species Reactivity Size 100 µg Tested species reactivity Mouse Host / Isotype Goat / IgG Tested Applications Dilution * Class Polyclonal Immunohistochemistry (Frozen) 5-15 µg/ml Type Antibody (IHC (F)) Mouse myeloma cell line Immunoprecipitation (IP) 25 µg/ml Immunogen NS0-derived recombinant mouse Trypsin 3 Phe16-Asn246 Western Blot (WB) 0.1 µg/ml Conjugate Unconjugated * Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls. Form Lyophilized Concentration 0.2mg/ml Purification Antigen affinity chromatography Storage Buffer PBS with 5% trehalose Contains No Preservative Storage Conditions -20° C, Avoid Freeze/Thaw Cycles Product Specific Information In Western blots, approximately 20% cross-reactivity with recombinant human (rh) Trypsin 1, rhTrypsin 2, and rhTrypsin 3 is shown. Reconstitute at 0.2 mg/mL in sterile PBS. Background/Target Information PRSS3 encodes a trypsinogen, which is a member of the trypsin family of serine proteases. This enzyme is expressed in the brain and pancreas and is resistant to common trypsin inhibitors. It is active on peptide linkages involving the carboxyl group of lysine or arginine. PRSS3 is localized to the locus of T cell receptor beta variable orphans on chromosome 9. Four transcript variants encoding different isoforms have been described for this gene. For Research Use Only.
    [Show full text]
  • HER-2 Overexpression Differentially Alters
    Available online http://breast-cancer-research.com/content/7/6/R1058 ResearchVol 7 No 6 article Open Access HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells Cindy A Wilson1, Elaina E Cajulis2, Jennifer L Green3, Taylor M Olsen1, Young Ah Chung2, Michael A Damore2, Judy Dering1, Frank J Calzone2 and Dennis J Slamon1 1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 2Amgen Inc., Thousand Oaks, CA 91320, USA 3Department of Biology, California Institute of Technology, Pasadena, CA 91125, USA Corresponding author: Cindy A Wilson, [email protected] Received: 20 Jul 2005 Revisions requested: 23 Aug 2005 Revisions received: 27 Sep 2005 Accepted: 6 Oct 2005 Published: 8 Nov 2005 Breast Cancer Research 2005, 7:R1058-R1079 (DOI 10.1186/bcr1343) This article is online at: http://breast-cancer-research.com/content/7/6/R1058 © 2005 Wilson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction Amplification of the HER-2 receptor tyrosine binding assays, phospho-specific Smad antibodies, kinase has been implicated in the pathogenesis and aggressive immunofluorescent staining of Smad and Smad DNA binding behavior of approximately 25% of invasive human breast assays. cancers. Clinical and experimental evidence suggest that aberrant HER-2 signaling contributes to tumor initiation and Results We demonstrate that cells engineered to over-express disease progression.
    [Show full text]
  • Structure Of
    University of Birmingham Structure of SPH (Self-Incompatibility Protein Homologue) proteins, a widespread family of small, highly stable, secreted proteins Rajasekar, Karthik; Ji, Shuangxi; Coulthard, Rachel J.; Ride, Jonathan; Reynolds, Gillian ; Winn, Peter; Wheeler, Michael; Hyde, Eva; Smith, Lorna J. DOI: 10.1042/BCJ20180828 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Rajasekar, K, Ji, S, Coulthard, RJ, Ride, J, Reynolds, G, Winn, P, Wheeler, M, Hyde, E & Smith, LJ 2019, 'Structure of SPH (Self-Incompatibility Protein Homologue) proteins, a widespread family of small, highly stable, secreted proteins', Biochemical Journal, vol. 476, no. 5, pp. 809-826. https://doi.org/10.1042/BCJ20180828 Link to publication on Research at Birmingham portal General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • PRSS2) Variant Protects Against Chronic Pancreatitis
    LETTERS A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis Heiko Witt1,2,39, Miklo´s Sahin-To´th3,39, Olfert Landt4, Jian-Min Chen5, Thilo Ka¨hne6, Joost PH Drenth7, Zolta´n Kukor3, Edit Szepessy3, Walter Halangk8, Stefan Dahm9, Klaus Rohde9, Hans-Ulrich Schulz8,Ce´dric Le Mare´chal5, Nejat Akar10, Rudolf W Ammann11, Kaspar Truninger11,12, Mario Bargetzi13, Eesh Bhatia14, Carlo Castellani15, Giulia Martina Cavestro16, Milos Cerny17, Giovanni Destro-Bisol18, Gabriella Spedini18, Hans Eiberg19, Jan B M J Jansen7, Monika Koudova20, Eva Rausova20, Milan Macek Jr20,Nu´ria Malats21, Francisco X Real21, Hans-Ju¨rgen Menzel22, Pedro Moral23, Roberta Galavotti24, Pier Franco Pignatti24, Olga Rickards25, Julius Spicak26, Narcis Octavian Zarnescu27, Wolfgang Bo¨ck28, Thomas M Gress28, Helmut Friess29, Johann Ockenga30, Hartmut Schmidt30,31, Roland Pfu¨tzer32, Matthias Lo¨hr32, Peter Simon33, Frank Ulrich Weiss33, Markus M Lerch33, Niels Teich34, Volker Keim34, Thomas Berg1, Bertram Wiedenmann1, Werner Luck2, David Alexander Groneberg2, Michael Becker35, Thomas Keil36, Andreas Kage37, Jana Bernardova1,2, Markus Braun1,2, Claudia Gu¨ldner1,2, Juliane Halangk1, Jonas Rosendahl2,34, Ulrike Witt38, Matthias Treiber1,2, Renate Nickel2 & Claude Fe´rec5 http://www.nature.com/naturegenetics Chronic pancreatitis is a common inflammatory disease overrepresented in control subjects: G191R was present of the pancreas. Mutations in the genes encoding cationic in 220/6,459 (3.4%) controls but in only 32/2,466 (1.3%)
    [Show full text]